1. Introduction
Bupleurum is a genus of the Apiaceae, comprising about 200 species. In China, about 44 species, 17 varieties, and 7 forma have been identified and are distributed widely across the country in 27 provinces [1,2]. Chaihu (Bupleuri Radix), the dried roots of Bupleurum chinense DC. and B. scorzonerifolium willd., is a famous Traditional Chinese medicinal herb with a history of medical use for more than 2000 years. Its main bioactive metabolites are saikosaponins and flavonoids. Saikosaponins and flavonoids are the main effective components of Bupleurum, and they can help treat diseases [3]. To measure the quality of Bupleurum, HPLC and GC-MS can be used to identify saikosaponins and flavonoids in Bupleurum [4,5]. This traditional method for the identification of the quality of Bupleurum could not be used to detect the spatial distribution of saikosaponins or other components in Bupleurum.
The spatial distribution of the main effective components of medicinal plants is important information regarding medicinal plants. Studies on the spatial distribution of saikosaponins and other effective components in Bupleurum provide direct information on the state of different growth stages of Bupleurum. The information can help with the study of the physiological and biochemical characteristics of saikosaponins and develop drugs based on saikosaponins.
MALDI-MSI technology has the ability to obtain specific images of metabolite molecules, without special labeling and staining, which is very convenient and fast. It has become an important technology to characterize the spatial characteristics of active components of medicinal plants, and has shown great potential in many research fields [6,7,8]. MALDI-MSI has made important contributions in many fields of biological science and has become a new research direction of plant metabonomics [9,10]. The main function of MALDI-MSI is to capture various chemical components in the space of biological tissues [11,12]. MALDI-MSI technology is constantly being updated and developed, including the development of MS instruments with higher resolution and higher sensitivity. These technologies make proteins, lipids, and various secondary metabolites in biological tissues and cells show specific spatial and temporal changes [13,14,15].
The achievements of MALDI-MSI technology in the research of medicinal plant pharmacological components have made it possible to use this technology to study the synthesis pathway of saikosaponins. MALDI-MSI imaging can be used to study the content and space distribution of maytansinoids in different plant species of Celastraceae to expand the source of maytansinoids [16]. MALDI-MSI was used to understand the space distribution of xanthones and bifidus flavonoids in thin sections of G. biloba leaves. The results indicate that G. biloba leaves also contain pharmacodynamic components to be used as drugs [17]. High-resolution MALDI mass spectrometry imaging of gallic acid and monoterpene glycosides in Paeonia lactiflora and Glycyrrhiza uralensis roots provides important clues for understanding the biosynthetic pathway of gallic acid and monoterpene glycosides [18]. The spatiotemporal localization of flavonoid metabolites in strawberry fruits revealed that flavonoids only existed in red fruits, thus indicating that mature fruits were more beneficial to people’s health [19].
Here, we researched the distribution of bioactive metabolites in three Bupleurum roots by MALDI-MSI. Bupleurum chinense (BC) is a typical medicinal plant that can soothe the liver, regulate qi, activate blood circulation, and relieve pain. Clinically, it is mainly used to treat depression, Alzheimer’s disease, functional dyspepsia, and cardiovascular and gynecological diseases [20]. The bioactive metabolites of Bupleurum contain saikosaponins, polysaccharides, total flavonoids, volatile oils, and other components, but saikosaponins are the most prevalent and the main component of its efficacy [21]. Bupleurum is widely planted in China. There are many species in the genus Bupleurum, and different contents of pharmacodynamic components in Bupleurum lead to large differences in their pharmacodynamics [22]. Although the difference in components of various Bupleurum species has been studied, the spatial distribution of these components in the secondary metabolism process has not yet been elucidated. Here, three species of the genus Bupleurum were used to measure the differences in their components and the spatial distribution of the main pharmacodynamic components including saikosaponins A, B, C, and D.
2. Results
2.1. Detection of Saikosaponins, Non-Saikosaponins, and Saikosaponin Synthesis Pathway Compounds by MALDI-TOF MS
B. smithii (BS), B. marginatum var. stenophyllum (BM), and BC were analyzed by MALDI-MS (Figure 1). The mass spectra of saikosaponins, saikosaponin synthesis pathway compounds, and non-saikosaponin components exhibit distinct characteristics across the three species of Bupleurum, offering compelling evidence for their identification and differentiation. The saikosaponins, non-saikosaponins, and saikosaponin synthesis pathway compounds of the three Bupleurum roots were tentatively determined based on their molecular weight measurements, MS/MS fragmentation patterns, and characteristic fragment ions. There were 12, 12, and 14 peaks for BS, BM, and BC, respectively. These were identified as saikosaponins, non-saikosaponins, and saikosaponin synthesis pathway compounds (Table 1). The detected ions were prominently in the potassium, sodium, and hydrogen adduct forms of saikosaponins, non-saikosaponins, and saikosaponin synthesis pathway compounds. Some common peaks were identified as saikosaponin A (m/z 951.5), saikosaponin B3 (m/z 813.5), saikosaponin C (m/z 765.5), saikosaponin E/F (m/z 803.4), saikosaponin F/E (m/z 803.5), non-saikosaponin (m/z 611.2, m/z 579.2, m/z 487.2, m/z 245.0, and m/z 205.1), and saikosaponin synthesis pathway compounds (m/z 472.2, m/z 269.0, m/z 232.0, m/z 201.0, and m/z 171.1).
2.2. Statistical Analysis of Variables for Saikosaponins, Non-Saikosaponins, and Saikosaponin Synthesis Pathway Compounds in the Three Bupleurum Species
It can be seen from Figure 2 that the OPLS-DA model distinguished the three Bupleurum samples. In addition, this study also conducted the OPLS-DA model verification, in which the replacement test n = 200. The results show that R2 = 0.0111, Q2 = −0.411, R2 and Q2 on the right are higher than those on the left, and Q2 intersects with the Y-axis on the negative axis, indicating that the model is reliable and does not have overfitting phenomenon (Supplementary Materials Figure S1). At the same time, the VIP value is used as the criterion for screening differential metabolites. If the VIP value is greater than 1, it indicates that this compound can be used as the differential component of the three samples. It can be seen from the Supplementary Materials Figure S2 that the VIP values of saikosaponin C (m/z 765.5), saikosaponin E/F (m/z 803.4), saikochromic acid (m/z 245.0), dimethoxy-isoflavane-7-o-β-D-glucoside (m/z 487.2), (R)-mevalonic acid (m/z 171.1), isopentenyl pyrophosphate (m/z 269.0), mevalonate-5-phosphate (m/z 201.0), tryptophan (m/z 205.1), and mevalonate-5-pyrophosphate (m/z 232.0) are greater than 1. The VIP values are as follows: 1.22, 1.20, 1.17, 1.14, 1.07, 1.07, 1.07, 1.06, and 1.06, respectively.
2.3. Determination of Saponins in Bupleurum by HPLC
The linear regression data and results are detailed in Table 2. Optimized chromatographic conditions ensured the clear resolution of these components, as shown in the chromatograms of control and test samples presented in Figure 3. Among the nine components, the highest saikosaponin A content was found in BS and BM, which have 2.84 and 2.80 mg·g−1, respectively. BM had the highest saikosaponin C content at 3.21 mg·g−1. BS and BC had the lowest saikosaponin B2 content of 0.1 and 0.13 mg·g−1, respectively.
It can be seen from the experimental results that there are degrees of differences in the content of the measured components in the B. radix samples from different origins, the content of saikosaponin B3 in different sources is relatively large, and the difference between saikosaponin B1 and saikosaponin E is relatively small. This shows that the difference in the content of saikosaponin B3 is closely related to the place of origin (Table 3).
2.4. Localization of Saikosaponin in the Root Tissues of the Three Bupleurum Species
The mass spectrometry data showed that the chemical components contained in the three Bupleurum species were similar (Figure 4). This indicates that the pharmacodynamic components of these species are comparable. However, the targeted results showed significant differences in the composition and content of some compounds. There are 12 kinds of saikosaponins in BC: saikosaponin A, B1, B2, B3, B4, C, D, E, F, G, H, and I. Similar mass-to-charge ratios were found in some groups of saikosaponins, e.g., saikosaponins A, B1, B2, and D; B3 and B4; F, H, and I; E and G. The mass-to-charge ratio of saikosaponin C differed from the others. Twelve saikosaponins distributed in the periderm, phloem, and xylem of roots were detected in BC at high concentration. Only saikosaponins A, E, and F were detected in BM. Saikosaponin B3 and C were not observed in the root of BM. The MALDI-MSI results of BS were consistent with those of BM, only saikosaponins A, E, and F were detected at low abundance.
2.5. Localization of Saikosaponin Synthesis Pathway Compounds in the Three Bupleurum Root Tissues
The content of saikosaponin synthesis pathway compounds in BC was abundantly distributed in the periderm, phloem, and xylem of roots (Figure 5). Four compounds-(R)-mevalonic acid, mevalonate-5-phosphate, mevalonate-5-diphosphate and isopentenyl pyrophosphate-were detected in BC, but farnesyl pyrophosphate was not observed. The five compounds were detected in BS and BM, but the content was significantly lower than in BC.
2.6. Localization of Non-Saikosaponin Compounds in the Three Bupleurum Root Tissues
Five non-saikosaponin compounds were detected, including 7,2′-dihydroxy-3′,4′-dimethoxy-isoflavane-7-o-β-D-glucoside, saikochromic acid, kaempferitrin, rutin, and tryptophan in BS, BM, and BC, but the content differed (Figure 6). The most abundant non-saikosaponin was observed in all parts of BC roots, while the content of BM and BS was significantly reduced and only seen in the cortex near the periderm. There was almost none in the phloem and xylem.
2.7. Cluster Analysis of Different Components
The expression of the same compound in different Bupleurum species and different compounds in the same species are shown in Figure 7. We used the average value of the compound expression of the same Bupleurum sample as a benchmark: expression above the average value is positive and marked in red. Expression below the average is negative and marked in blue. The color depth indicates the difference between the expression amount of the compound and the average value. The expression of saikosaponins A, B1, B3, C, E, and F in BC was significantly higher than the average value, while the expression of saikosaponins in BS and BM was lower than the average value. However, the saikosaponin synthesis pathway compounds FPP, quercetin, tryptophan, MDP, (R)-mevalonic acid, MP and IPP had higher expression in BS and lower expression in BM and BC. Only the expression of puerarin and saikosaponin H was higher than the average expression in BM. Saikonchromic acid, isorhamnetin, kaempferitrin, and rutinum were lightly expressed in BC and BS, and were expressed less in BM. The saikosaponin content is the most important indicator to assess the quality of B. radix; thus, the quality of BC is better than that of BS and BM.
3. Discussion
The main effective component of B. radix is Bupleurum saikosaponin [21]. Twelve Bupleurum saikosaponins were reported, namely saikosaponin A, B1, B2, B3, B4, C, D, E, F, G, H, and I [4], (Supplementary Materials Figure S3). Saikosaponins have different pharmacological effects. Saikosaponin A has anti-human neuroblastoma effects and limits bladder cancer cell growth [20,23]. Saikosaponins A and D can inhibit lipogenesis [24]. Saikosaponins A, B, and D can restrict the growth of transplanted mouse medulloblastoma [25]. Saikosaponins F and G also have different anti-cancer effects [26].
Bupleurum saikosaponin is the main active ingredient and an important secondary metabolite of B. radix. The MALDI analysis showed variations in the distribution of saikosaponin in different Bupleurum species. BC contains all types of Bupleurum saponins (Figure 4; m/z 803.4, m/z 813.5, m/z 803.5, m/z 765.5, and m/z 951.5) in all areas of roots. BM does not contain Bupleurum saikosaponins B and C (Figure 4; m/z 813.5 and m/z 765.5); there is only a trace amount of the other saikosaponins near the periderm of the root and almost none in the xylem. The distribution and content of saikosaponins in BS and BM were similar. The quality of BS is the best among the three species in terms of saikosaponin content.
Saikosaponins are secondary metabolites of Bupleurum. Transcriptomic and metabolomics studies have found some key enzymes and compounds in the synthetic pathway of saikosaponin [27,28,29]. MALDI was used to characterize some compounds in the saikosaponin synthesis pathway of Bupleurum roots (Supplementary Materials Figure S4). This could nicely display the position and content of these compounds in Bupleurum roots. Here, (R)-mevalonic acid was mainly distributed in the periderm and phloem of BS and the periderm, phloem, and xylem of BC; it was only seen in the xylem of BM (Figure 5, m/z 171.1). Mevalonate-5-phosphate is only distributed in the xylem of BS and BM. The entire root area of BC has high levels of mevalonate-5-phosphate (Figure 5, m/z 201.0). Mevalonate-5-pyrophosphate and isopentenyl pyrophosphate are mainly distributed in the periderm and phloem of BS and BM as well as in the entire root of BC (Figure 5; m/z 232.0, m/z 269.0). However, it is puzzling that farnesyl pyrophosphate is distributed in the whole root of BS and BM despite its low content. Farnesyl pyrophosphate is not detected in BC (Figure 5; m/z 472.2). A possible explanation is that BC has not yet formed farnesyl pyrophosphate, which also indicates the time difference in saikosaponin for the formation of these Bupleurum species. The analysis of the key compounds of the saikosaponin synthesis pathway also showed that BC had the best quality of saikosaponin.
Saikosaponins are triterpenoid saponins of the oleanane type. The pathway of their synthesis has been studied in detail (Figure 8). This pathway is called the MVA pathway. MVA is an important site in the metabolism of cytoplasmic terpenoids. MVA forms IPP and DMAPP through a series of reactions. They are precursors of all terpenoids and steroids. IPP and DMAPP further formed FPP under the catalysis of isopentenyl transferase, and FPP finally produced triterpene saponins through a series of downstream reactions. In this study, MVA, MVAP, MVAPP, IPP, and FPP were detected in BS, BM, and BC by MALDI-MS technology (Figure 8), indicating that the three Bupleurum species have the same synthetic process of saikosaponin, but the amount of products are different. The content of the saikosaponin synthesis pathway compounds indicates the final quantity of saikosaponin, which provides a basis for determining the quality of Bupleurum. Meanwhile, the results also revealed that certain compounds in the synthetic pathway were not detected, especially in the FPP pathway, e.g., beta-AS, 2,3-oxidosqualene and squalene. It was speculated that the reason for this might be the incompatibility of the chemical structures of 2-MBT with individual compounds in the FPP pathway, which resulted in the inability of these compounds to be efficiently ionized or to produce characteristic signals in the mass spectra.
There are a few non-saikosaponins in Bupleurum including 7,2′-dihydroxy-3′,4′-dimethoxy-isoflavane-7-o-β-D-glucoside, Bupleurum xanthan ketonic acid, kaempferitrin, baicalin, rutin, tryptophan, quercetin, isorhamnetin 3-o-glucoside, isorhamnetin, and puerarin (Supplementary Materials Figure S5) [30]. Five non-saikosaponin components were identified in BS, BM, and BC by the MALDI-MSI technology including 7,2′-dihydroxy-3′,4′-dimethoxy-isoflavane-7-o-β-D-glucoside (Figure 6, m/z 487.2), saikochromic acid (Figure 6, m/z 245.0), kaempferitrin m/z 579.2), rutin (Figure 6, m/z 611.2), and tryptophan (Figure 6, m/z 205.1). In BS, BM, and BC, these components are all located in the periderm and phloem of roots with a trace abundance in the xylem. The content of these components in BC was significantly higher than that in BS and BM. Although the non-saikosaponin components are not the main pharmacodynamic components of BC, they still have certain pharmacological effects. In conclusion, the quality of BC is better than that of BS and BM.
4. Materials and Methods
4.1. Materials
Seeds of Bupleurum smithii (BS), B. marginatum var. stenophyllum (BM), and B. chinense (BC) were purchased from Inner Mongolia, Gansu, and Hebei Provinces, respectively. They were planted in the Medicinal Plant Resource Garden of Hebei Academy of Agricultural and Forestry Sciences, Shijiazhuang, Hebei province, China (38.04228 N 114.5144 E) on August 2021. Each Bupleurum species was planted in a single plot: three rows that were 3 m long with 1.5 m between rows. Thirty seeds were sown in each row. After growing for 1 year, the roots were collected for MALDS-MSI in July 2022. Three seedlings were taken from each row of a community, and thus nine seedlings were sampled from each Bupleurum species.
Saikosaponin standards were purchased from Shanghai Yuanye Bio-Technology Co., Ltd., Shanghai, China (
4.2. Tissue Sectioning
Clean the fresh Bupleurum roots, remove the fibrous roots, and cut them transversely into segments about 0.5 cm in length. Embed the freshly cut tissue with OCT (Optimal Cutting Temperature) freezing section embedding agent on the sample tray of the cryostat, and place it on the ultra-low temperature freezing stage (−20 °C, Leica Microsystems Inc., Wetzlar, Germany) inside the cryostat for 10 min. Cut into 12 μm thick adjacent sections of Bupleurum root tissue, then transfer them onto ITO (indium tin oxide) coated conductive glass slides (Bruker Daltonics, Billerica, MA, USA), and vacuum dry for 20 min.
4.3. Matrix Coating and Microscopy Visualization
A 10 mg/mL solution of 2-mercaptobenzothiazole (2-MBT) was formulated using a methanol-to-water solvent blend at an 80:20 ratio by volume, supplemented with 0.2% trifluoroacetic acid (TFA). The application of this matrix to the tissue sections of Bupleurum was executed with an automated spotter, the ImagePrep, from Bruker Daltonics, in Bremen, Germany. To achieve a consistent and thin layer of matrix, a continuous spray application was administered for a duration of 5 s, succeeded by a 60 s interval for evaporation. This process was iterated five times. Post-initial cycles and after natural air drying in a ventilated area, another 40 cycles of even matrix spraying were applied to the tissue sections.
4.4. MALDI-MSI
The instrument used for all profile and imaging experiments is a Bruker Autoflex Speed MALDI time-of-flight (TOF)/TOF mass spectrometer (Bruker Daltonics). The mass range of all mass spectra is m/z 100 to 3500. Use 20 laser scanning accumulations to record the mass spectrum to obtain the profile data of MALDI-MS. For imaging data acquisition, endogenous low-MW compounds in the Bupleurum root tissue sections were detected by 100 μm laser raster step-sizes. The compounds used for external mass calibration and their m/z value: Pro ([M + H]+, m/z 116.1), bradykinin 1−7 ([M + H]+, m/z 757.4), angiotensin II ([M + H]+, m/z 1046.5), angiotensin I ([M + H]+, m/z 1296.7), substance P ([M + H]+, m/z 1347.7), and bombesin ([M + H]+, m/z 1619.8). Matrix ions of DMCA ([M + H]+, m/z 209.1) and 2-MBT ([M + H]+, m/z 168.0) were used for an internal mass calibration. The calibration is the cubic-enhanced mode.
4.5. Data Analysis
Profiling data of saikosaponin, non-saikosaponin, and saikosaponin synthesis pathway compounds were checked and treated by the Bruker FlexAnalysis 3.4 software (
4.6. Histological Staining
After the MALDI-MS experiment, the matrix on all tissue sections was cleaned with methanol solution of three concentrations (70%, 90%, and 100%), and then stained with hematoxylin and eosin. The results of the H&E staining are shown in the Supplementary Materials Figure S6.
4.7. Preparation of Standard Compounds
Standard solutions of 12 saikosaponins, 10 non-saikosaponins, and 8 saikosaponin synthesis pathway compounds were prepared for MALDI-TOF MS detection. Details of the standards are given in the Supplementary Materials Figures S3–S5.
4.8. Extraction and Content Determination of Saikosaponins by HPLC
The saponins were extracted from Bupleurum roots using HPLC and their contents were determined. The detailed extraction process and chromatographic conditions are recorded in the Supplementary Materials.
5. Conclusions
The evaluation of medicinal plants is inherently challenging, with the production of efficacious components being influenced by cultivation methods and plant species. While HPLC and GC-MS methods have been employed to quantify the content of various components in B. radix, differentiating between varieties of B. radix remains non-intuitive. However, MALDI-MSI offers a visual characterization of the differences between the three Bupleurum species, including BC, which has been found to be superior in quality to BS and BM. This technique has been used to detect twelve saikosaponins, five non-saikosaponins, and five saikosaponin synthesis pathway compounds in these species. By analyzing the quality and the spatial distribution of pharmacodynamic substances, MALDI-MSI provides a direct observation and calibration method for the effective components of medicinal plants.
Conceptualization, X.H. and D.M.; methodology, J.W.; software, L.P.; validation, L.L., W.S. and Z.R.; formal analysis, X.W.; investigation, Y.Z. (Ye Zhang); resources, Y.Z. (Yuguang Zheng); writing—original draft preparation, X.H.; writing—review and editing, D.M.; project administration, H.S. All authors have read and agreed to the published version of the manuscript.
Not applicable.
Not applicable.
The data presented in this study are available in the article and
Thanks to researcher Hongjie Li from the Institute of crop science, Chinese Academy of Agricultural Sciences for modifying the language of the paper.
The authors declare no conflicts of interest.
Footnotes
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Enlarge this image.Figure 1. The overall average mass spectra of the three Bupleurum species obtained by MALDI-MS.
Enlarge this image.Figure 3. HPLC chromatograms of reference compound (A), BS (B), BM (C), and BC (D). 1—saikosaponin C; 2—saikosaponin F; 3—saikosaponin B3; 4—saikosaponin A; 5—saikosaponin B2; 6—saikosaponin G; 7—saikosaponin B1; 8—saikosaponin E; 9—saikosaponin D.
Enlarge this image.Figure 4. The localization of saikosaponin ions in the root tissues of the three Bupleurum species by MALDI-MSI. CH1: BS; CH2: BM; and CH3: BC.
Enlarge this image.Figure 5. The localization of saikosaponin synthesis pathway compound ions in the root tissues of the three Bupleurum species by MALDI-MSI. CH1: BS; CH2: BM; and CH3: BC.
Enlarge this image.Figure 6. The localization of non-saikosaponin ions in the root tissues of the three Bupleurum species by MALDI-MSI. CH1: BS; CH2: BM; and CH3: BC.
Enlarge this image.Figure 7. Cluster heatmap of chemical constituents of the three Bupleurum species. FPP: farnesyl pyrophosphate; MDP: mevalonate-5-diphosphate; MP: mevalonate-5-phosphate; IPP: isopentenyl pyrophosphate; RG: isorhamnetin-3-O-glucoside; and DIG: 7,2′-dihydroxy-3′,4′-dimethoxy-isoflavane-7-o-β-D-glucoside. CH1: BS; CH2: BM; CH3: BC.
Enlarge this image.Figure 8. Synthetic pathway of saikosaponin (the compounds in the red box are the compounds identified in this experiment). MVA: mevalonic acid, MVAP: mevalonate-5-phosphate, MVAPP: mevalonate-5-pyrophosphate, DMAPP: dimethylallyl diphosphate, IPP: isopentenyl diphosphate, FPP: farnesyl pyrophosphate, β-AS: β-amyrin.
Saikosaponin, non-saikosaponin, and saikosaponin synthesis pathway compounds detected in the three Bupleurum species by MALDI-TOF-MSI and confirmed by MALDI-TOF-MS/MS.
| Measured | Calculated | Error | Identification | Localization | CID | ||||
|---|---|---|---|---|---|---|---|---|---|
| Ion Form | Compound | Molecular | BS | BM | BC | ||||
| 951.5 | 951.5287 | 2 | [M + Na]+ | Saikosaponin A | C48H80O17 | Periderm | Periderm | Periderm and phloem | 365.1; 451.1; 511.2; 805.5; 919.3 |
| 803.4 | 803.4342 | 3 | [M + K]+ | Saikosaponin E/F | C42H68O12 | Periderm | Periderm | Periderm, phloem, and cambium | 203.1; 331.2; 349.1; 757.4 |
| 813.5 | 813.4994 | 2 | [M + H]+ | Saikosaponin B3 | C43H72O14 | - | - | Periderm, phloem, and cambium | 133.1; 251.1; 309.1; 559.4; 705.5 |
| 803.5 | 803.4552 | 1 | [M + Na]+ | Saikosaponin E/F | C42H68O13 | Periderm | Periderm | Periderm, phloem, and cambium | 455.4; 437.3; 456.3 |
| 765.5 | 765.4783 | 1 | [M + H]+ | Saikosaponin C | C48H78O18 | - | - | Periderm, phloem, and cambium | 189.2; 255.1; 403.3; 649.9 |
| 611.2 | 611.1606 | 1 | [M + H]+ | Rutin | C27H30O16 | - | - | Periderm, phloem, and cambium | 303.0; 611.0; 612.0 |
| 579.2 | 579.1708 | 4 | [M + H]+ | Kaempferitrin | C27H30O14 | Periderm, phloem, and cambium | Periderm, phloem, and cambium | Periderm, phloem, and cambium | |
| 487.2 | 487.24 | 1 | [M + Na]+ | 7,2′-Dihydroxy-3′,4′-dimethoxy-isoflavane-7-o-β-D-glucoside | C23H28O10 | Periderm, phloem, cambium, and xylem | Periderm, phloem, cambium, and xylem | Periderm, phloem, cambium, and xylem | |
| 472.2 | 472.1738 | 7 | [M + K]+ | Farnesyl pyrophosphate | C15H37N3O7P2 | Periderm, phloem, cambium, and xylem | Periderm, phloem, cambium, and xylem | - | 160.9; 365.1; 383.2 |
| 269.0 | 268.9950 | 4 | [M + Na]+ | Isopentenyl pyrophosphate | C5H12O7P2 | Periderm, phloem, and cambium | Periderm, phloem, and cambium | Periderm, phloem, cambium, and xylem | 161.1; 229.0 |
| 245.0 | 245.06 | 2 | [M + Na]+ | Saikochromic acid | C10H6O6 | Periderm, cambium, and xylem | Periderm, cambium, and xylem | Periderm, phloem, and cambium | |
| 232.0 | 232.05 | 2 | [M + Na]+ | Mevalonate-5-pyrophosphate | C6H12O2P2 | Periderm, phloem, and cambium | Periderm, phloem, and cambium | Periderm, phloem, cambium, and xylem | |
| 205.1 | 205.11 | 4 | [M + H]+ | Tryptophan | C11H12N2O2 | Periderm | Periderm | Periderm, phloem, cambium, and xylem | 143.9; 145.9; 151.0; 187.9; 204.9 |
| 201.0 | 201.07 | 3 | [M + Na]+ | Mevalonate-5-phosphate | C6H12O2P | Xylem | Xylem | Periderm, phloem, cambium, and xylem | |
| 171.1 | 171.0627 | 2 | [M + Na]+ | (R)-Mevalonic acid | C6H12O2 | Periderm and phloem | Xylem | Periderm, phloem, cambium, and xylem | 108.0; 149.7 |
Regression data of nine saponins.
| Analyte | Linear Range/(mg·mL−1) | Regression Equation | r |
|---|---|---|---|
| Saikosaponin C | 0.21~1.11 | Y = 1198.8X − 25.776 | 0.9985 |
| Saikosaponin F | 0.18~0.96 | Y = 1145.5X + 26.776 | 0.9998 |
| Saikosaponin B3 | 0.27~0.94 | Y = 1214.1X − 5.034 | 0.9949 |
| Saikosaponin A | 0.22~1.17 | Y = 1756.2X − 0.239 | 0.9990 |
| Saikosaponin B2 | 0.26~1.35 | Y = 1652.9X − 7.000 | 0.9999 |
| Saikosaponin G | 0.22~1.17 | Y = 2223.2X − 41.657 | 0.9990 |
| Saikosaponin B1 | 0.19~1.02 | Y = 1341.6X − 43.723 | 0.9994 |
| Saikosaponin E | 0.19~0.99 | Y = 1831.8X − 38.310 | 0.9990 |
| Saikosaponin D | 0.14~0.72 | Y = 742.61X − 37.835 | 0.9991 |
Sample determination result (mg·g−1).
| Sample | Saikosaponin C | S. F | S. B3 | S. A | S. B2 | S. G | S. B1 | S. E | S. D |
|---|---|---|---|---|---|---|---|---|---|
| BS | 0.34 b ± 0.03 | 1.03 a ± 0.06 | 0.55 a ± 0.03 | 2.84 a ± 0.11 | 0.10 b ± 0.01 | 0.77 a ± 0.02 | 0.40 a ± 0.03 | 0.26 a ± 0.04 | 2.36 a ± 0.15 |
| BM | 3.21 a ± 0.12 | 1.05 a ± 0.06 | 0.12 c ± 0.01 | 2.80 a ± 0.08 | 0.29 a ± 0.03 | 0.54 b ± 0.03 | 0.38 a ± 0.02 | 0.32 a ± 0.04 | 2.49 a ± 0.14 |
| BC | 0.38 b ± 0.04 | 0.55 b ± 0.02 | 0.32 b ± 0.04 | 2.08 b ± 0.08 | 0.13 b ± 0.01 | 0.68 a ± 0.03 | 0.42 a ± 0.03 | 0.37 a ± 0.02 | 1.38 b ± 0.09 |
Note: This table presents the mean values and standard deviations. Mean values with different letters in the same column indicate statistically significant differences (p < 0.05).
Supplementary Materials
The following supporting information can be downloaded at:
References
1. Yao, R.Y.; Zou, Y.F.; Chen, X.F. Traditional use, pharmacology, toxicology, and quality control of species in genus Bupleurum L. Chin. Her. Med.; 2013; 5, pp. 245-255. [DOI: https://dx.doi.org/10.1016/S1674-6384(13)60036-2] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32288759]
2. Yu, D.; Wang, W.X.; Huo, J.H.; Zhuang, Y.; Chen, Y.Y.; Du, X.W. Study on molecular mechanism of volatiles variation during Bupleurum scorzonerifolium root development based on metabolome and transcriptome analysis. Front. Plant Sci.; 2023; 14, 1159511. [DOI: https://dx.doi.org/10.3389/fpls.2023.1159511] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/37035038]
3. Chinese Pharmacopeia Commission. Pharmacopoeia of the People’s Republic of China; China Medical Science and Technology Press: Beijing, China, 2020; Volume I.
4. Liu, Y.M.; Zhou, A.; Yu, N.J.; Han, R.C.; Zhang, W.; Zhu, Y.J.; Cao, Y.; Li, X.Y.; Peng, D.Y. Simultaneous determination of five saponins in Bupleuri Radix by HPLC-DAD dual wavelength method. China J. Chin. Mat. Med.; 2018; 43, pp. 363-368. [DOI: https://dx.doi.org/10.19540/j.cnki.cjcmm.20171027.001]
5. Deng, P.; Zheng, G.S.; Luo, X.J.; Wang, Y.S. Simultaneous determination of saikosaponins a, b2, c, d, f in Radix Bupleuri by HPLC. J. Jiangxi Univ.; 2013; 25, pp. 46-49.
6. Wu, C.P.; Dill, A.L.; Eberlin, L.S.; Cooks, R.G.; Ifa, D.R. Mass spectrometry imaging under ambient conditions. Mass Spectrom. Rev.; 2013; 32, pp. 218-243. [DOI: https://dx.doi.org/10.1002/mas.21360] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22996621]
7. Dong, Y.H.; Li, B.; Malitsky, S.; Rogachev, I.; Aharoni, A.; Kaftan, F.; Svatoš, A.; Franceschi, P. Sample preparation for mass spectrometry imaging of plant tissues: A review. Front. Plant Sci.; 2016; 7, 60. [DOI: https://dx.doi.org/10.3389/fpls.2016.00060] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26904042]
8. Van Hove, E.R.A.; Smith, D.F.; Heeren, R.M.A. A concise review of mass spectrometry imaging. J. Chromatogr. A.; 2010; 1217, pp. 3946-3954. [DOI: https://dx.doi.org/10.1016/j.chroma.2010.01.033]
9. Heyman, H.M.; Dubery, I.A. The potential of mass spectrometry imaging in plant metabolomics: A review. Phytochem. Rev.; 2016; 15, pp. 297-316. [DOI: https://dx.doi.org/10.1007/s11101-015-9416-2]
10. Kaspar, S.; Peukert, M.; Svatos, A.; Matros, A.; Mock, H.P. MALDI-imaging mass spectrometry—An emerging technique in plant biology. Proteomics; 2011; 11, pp. 1840-1850. [DOI: https://dx.doi.org/10.1002/pmic.201000756]
11. Cornett, D.S.; Reyzer, M.L.; Chaurand, P.; Caprioli, R.M. MALDI imaging mass spectrometry: Molecular snapshots of biochemicalsystems. Nat. Methods; 2007; 4, pp. 828-833. [DOI: https://dx.doi.org/10.1038/nmeth1094]
12. Lee, Y.J.; Perdian, D.C.; Song, Z.; Yeung, E.S.; Nikolau, B.J. Use of mass-spectrometry for imaging metabolites in plants. Plant J.; 2012; 70, pp. 81-95. [DOI: https://dx.doi.org/10.1111/j.1365-313X.2012.04899.x] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22449044]
13. Kompauer, M.; Heiles, S.; Spengler, B. Atmospheric pressure MALDI mass spectrometry imaging of tissues and cells at 1.4-μm lateral resolution. Nat. Methods; 2017; 14, pp. 90-96. [DOI: https://dx.doi.org/10.1038/nmeth.4071] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27842060]
14. Baker, T.C.; Han, J.; Borchers, C.H. Recent advancements in matrix-assisted laser desorption/ionization mass spectrometry imaging. Curr. Opin. Biotechnol.; 2017; 43, pp. 62-69. [DOI: https://dx.doi.org/10.1016/j.copbio.2016.09.003] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27690313]
15. Schwamborn, K.; Caprioli, R.M. Molecular imaging by mass spectrometry—Looking beyond classical histology. Nat. Rev. Cancer; 2010; 10, pp. 639-646. [DOI: https://dx.doi.org/10.1038/nrc2917] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20720571]
16. Eckelmann, D.; Kusari, S.; Spiteller, M. Occurrence and spatial distribution of maytansinoids in Putterlickia pyracantha, an unexplored resource of anticancer compounds. Fitoterapia; 2016; 113, pp. 175-181. [DOI: https://dx.doi.org/10.1016/j.fitote.2016.08.006] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27521896]
17. Beck, S.; Stengel, J. Mass spectrometric imaging of flavonoid glycosides and biflavonoids in Ginkgo biloba L. Phytochemistry; 2016; 130, pp. 201-206. [DOI: https://dx.doi.org/10.1016/j.phytochem.2016.05.005] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27233155]
18. Li, B.; Bhandari, D.R.; Römpp, A.; Spengler, B. High-resolution MALDI mass spectrometry imaging of gallotannins and monoterpeneglucosides in the root of Paeonia lactiflora. Sci. Rep.; 2016; 6, 36074. [DOI: https://dx.doi.org/10.1038/srep36074]
19. Crecelius, A.C.; Hölscher, D.; Hoffmann, T.; Schneider, B.; Fischer, T.C.; Hanke, M.V.; Flachowsky, H.; Schwab, W.; Schubert, U.S. Spatial and temporal localization of flavonoid metabolites in strawberry fruit (Fragaria × ananassa). J. Agric. Food Chem.; 2017; 65, pp. 3559-3568. [DOI: https://dx.doi.org/10.1021/acs.jafc.7b00584] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28409937]
20. Zhou, Q.; Wu, W.W.; Yu, C.L.; Wang, P.; Wen, X.Q.; Chen, B.L.; Zhang, Y.; Zhuang, M.; Zhang, M.Y.; Zhang, H.Y. et al. Saikosaponin A inhibits growth of human bladder carcinoma T24 and 5637 cells both in vitro and in vivo. Biol. Pharm. Bull.; 2022; 45, pp. 863-871. [DOI: https://dx.doi.org/10.1248/bpb.b21-01025]
21. Zhao, H.; Wang, X.; Zhang, Y.; Huang, X.; Jiang, Y.; Ma, H.; An, L.; Wu, X.; Wang, Q. Quantitative 1H NMR for the direct Quantification of saikosaponins in Bupleurum chinense DC. Anal. Sci.; 2021; 37, pp. 1413-1418. [DOI: https://dx.doi.org/10.2116/analsci.20P462]
22. Xia, Z.D.; Liu, X.; Tong, L.G.; Wang, H.; Feng, M.L.; Xi, X.H.; He, P.; Qin, X.M. Comparison of chemical constituents of Bupleurum marginatum var. stenophyllum and Bupleurum chinense DC. using UHPLC-Q-TOF-MS based on a metabonomics approach. Biomed. Chromatogr.; 2021; 35, e5133. [DOI: https://dx.doi.org/10.1002/bmc.5133]
23. Cheng, T.; Ying, M. Antitumor effect of saikosaponin A on human neuroblastoma cells. Biomed Res. Int.; 2021; 2021, pp. 5845554-5845565. [DOI: https://dx.doi.org/10.1155/2021/5845554] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34513994]
24. Lim, S.H.; Lee, H.S.; Han, H.K.; Choi, C.I. Saikosaponin A and D inhibit adipogenesis via the AMPK and MAPK signaling pathways in 3T3-L1 adipocytes. Int. J. Mol. Sci.; 2021; 22, 11409. [DOI: https://dx.doi.org/10.3390/ijms222111409] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34768840]
25. Luo, J.; Wang, J.; Yang, J.; Huang, W.J.; Liu, J.Q.; Tan, W.F.; Xin, H. Saikosaponin B1 and Saikosaponin D inhibit tumor growth in medulloblastoma allograft mice via inhibiting the Hedgehog signaling pathway. J. Nat. Med.; 2022; 76, pp. 584-593. [DOI: https://dx.doi.org/10.1007/s11418-022-01603-8] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/35171398]
26. Lee, J.E.; Song, B.K.; Kim, J.H.; Siddiqi, M.Z.; Im, W.T. Production of prosaikogenin F, prosaikogenin G, markogenin F and saikogenin G by the recombinant enzymatic hydrolysis of saikosaponin and their anti-cancer effect. Molecules; 2022; 27, 3255. [DOI: https://dx.doi.org/10.3390/molecules27103255]
27. Zhang, Q.; Li, M.; Chen, X.; Liu, G.; Zhang, Z.; Tan, Q.; Hu, Y.; Fan, Y.; Liu, Y.; Zhu, T. et al. Chromosome-Level genome assembly of Bupleurum chinense DC provides insights into the saikosaponin biosynthesis. Front. Genet.; 2022; 13, 878431. [DOI: https://dx.doi.org/10.3389/fgene.2022.878431] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/35432473]
28. Han, W.; Xu, J.; Wan, H.; Zhou, L.; Wu, B.; Gao, J.; Guo, X.; Sui, C.; Wei, J. Overexpression of BcERF3 increases the biosynthesis of saikosaponins in Bupleurum chinense. FEBS Open Bio.; 2022; 12, pp. 1344-1352. [DOI: https://dx.doi.org/10.1002/2211-5463.13412] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/35429231]
29. Liu, W.X.; Cheng, X.L.; Kang, R.; Wang, Y.D.; Guo, X.H.; Jing, W.G.; Wei, F.; Ma, S.C. Systematic characterization and identification of saikosaponins in extracts from Bupleurum marginatum var. stenophyllum using UPLC-PDA-Q/TOF-MS. Front. Chem.; 2021; 9, 747987. [DOI: https://dx.doi.org/10.3389/fchem.2021.747987]
30. Liang, H.; Zhao, Y.Y.; Cui, Y.J.; Liu, Q.X. Flavonoids from the roots of Bupleurum chinense DC. J. Beijing Med. Univ.; 2000; 32, pp. 223-225.
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Details
; Wang, Jiemin 1 ; Lin, Pei 2 ; Liu, Lingdi 3 ; Shi, Weihong 1 ; Zhengpu Rong 1 ; Wang, Xiaoyuan 1 ; Zhang, Ye 1 ; Zheng, Yuguang 1 ; Sun, Huigai 1 1 College of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang 050200, China;
2 Hebei Academy of Traditional Chinese Medicine, Shijiazhuang 050031, China;
3 Institute of Cash Crops, Hebei Academy of Agriculture and Forestry Sciences, Shijiazhuang 050051, China;